Buy Opana ER 20mg in UK Online

Opana ER 20mg is an extended-release (ER) formulation of oxymorphone hydrochloride, a strong opioid analgesic that was developed for the management of severe, persistent pain requiring continuous, around-the-clock opioid treatment. The extended-release formulation releases oxymorphone gradually over approximately 12 hours, providing sustained pain relief for patients with chronic pain when other treatment options are inadequate. (Drugs.com)

For readers in the United Kingdom, it is important to know that Opana ER is not licensed or routinely prescribed in UK clinical practice. In addition, the original Opana ER brand has been discontinued in the United States following regulatory action related to public health concerns about misuse and abuse. (Drugs.com)

What Is Opana ER 20mg?

Each extended-release tablet contains:

• Active ingredient: Oxymorphone hydrochloride
• Strength: 20 mg
• Medicine class: Strong opioid analgesic
• Dosage form: Extended-release (modified-release) oral tablet

Oxymorphone is a semi-synthetic opioid that acts on opioid receptors in the brain and spinal cord to reduce the perception of pain.

How Does Opana ER Work?

Oxymorphone primarily activates mu-opioid receptors, reducing the transmission of pain signals and altering how the brain responds to pain.

This may help:

• Reduce severe chronic pain
• Improve comfort in patients requiring long-term pain management
• Improve daily functioning when pain is appropriately controlled

Because it affects the central nervous system, oxymorphone can also cause sedation and slowed breathing.

Medical Uses

Where it was licensed, Opana ER was indicated for adults with pain that:

• Is severe enough to require around-the-clock opioid treatment
• Is expected to continue for an extended period
• Cannot be adequately controlled with non-opioid medicines or other therapies

It is not intended for:

• Mild pain
• Short-term pain
• Occasional pain
• Breakthrough pain
• “As-needed” pain relief

Extended-release opioids should only be prescribed when the expected benefits outweigh the risks. (Drugs.com)

Availability in the UK

Opana ER 20 mg is not licensed or routinely prescribed in the United Kingdom. When long-acting opioid therapy is required, UK healthcare professionals generally prescribe medicines licensed for UK use, such as prolonged-release morphine or oxycodone, depending on the patient’s individual circumstances. (GOV.UK)

How Should It Be Taken?

If prescribed in countries where oxymorphone ER is available:

• Take the medicine exactly as directed by your healthcare professional.
• Swallow the tablet whole with water.
• Do not crush, chew, split, or dissolve the tablet.

Damaging an extended-release tablet can release the entire dose immediately, greatly increasing the risk of overdose and life-threatening respiratory depression. (Drugs.com)

Common Side Effects

Like other opioid medicines, oxymorphone may cause:

• Constipation
• Nausea
• Vomiting
• Drowsiness
• Dizziness
• Dry mouth
• Headache
• Sweating

Constipation is one of the most common opioid-related side effects and may require preventive measures recommended by a healthcare professional.

Serious Side Effects

Seek emergency medical attention immediately if someone develops:

• Difficulty breathing
• Slow or shallow breathing
• Extreme sleepiness or inability to wake
• Blue lips or fingertips
• Loss of consciousness
• Severe allergic reaction

These symptoms may indicate an opioid overdose or another life-threatening emergency.

Dependence, Tolerance, and Addiction

Like all strong opioids, oxymorphone carries important risks, including:

• Tolerance, where higher doses may eventually be needed for the same effect.
• Physical dependence, where stopping suddenly can cause withdrawal symptoms.
• Opioid use disorder (addiction) in some people.

If long-term opioid therapy needs to be stopped, healthcare professionals usually recommend gradually reducing the dose rather than stopping abruptly.

Drug Interactions

Oxymorphone may interact with:

• Other opioid medicines
• Benzodiazepines
• Sleeping tablets
• Alcohol
• Muscle relaxants
• Certain antipsychotics
• Other medicines that cause drowsiness

These combinations can increase the risk of profound sedation, dangerously slowed breathing, coma, and death.

Alcohol

Alcohol should not be consumed while taking extended-release opioids because it can substantially increase the risk of:

• Severe drowsiness
• Respiratory depression
• Accidental overdose

(Drugs.com)

Driving

Do not drive or operate machinery if oxymorphone causes:

• Sleepiness
• Dizziness
• Poor concentration
• Slowed reaction times

Driving while impaired by opioids is unsafe and may be unlawful.

Pregnancy and Breastfeeding

If you are pregnant, planning pregnancy, or breastfeeding, discuss treatment options with your healthcare professional before taking any opioid medicine. Long-term opioid use during pregnancy may lead to neonatal opioid withdrawal syndrome after birth.

Storage

Store opioid medicines:

• In their original packaging.
• At room temperature.
• Away from heat and moisture.
• Securely and out of the sight and reach of children.

Unused tablets should be returned to a pharmacy for safe disposal.

Frequently Asked Questions

Is Opana ER 20 mg available in the UK?

No. Opana ER is not licensed or routinely prescribed in the UK. (Drugs.com)

Can Opana ER be used for sudden pain?

No. It is intended only for continuous management of severe chronic pain, not for occasional or breakthrough pain. (Drugs.com)

Can the tablet be crushed or split?

No. Extended-release tablets must always be swallowed whole. Crushing, chewing, or splitting them can rapidly release the full dose and greatly increase the risk of overdose. (Drugs.com)

Is the Opana ER brand still available?

The original Opana ER brand has been discontinued in the United States following FDA action, although generic oxymorphone extended-release products have existed in some markets.

Key Takeaways

Opana ER 20 mg is an extended-release oxymorphone tablet that was developed for the treatment of severe, persistent pain requiring continuous opioid therapy. It is not licensed or routinely prescribed in the UK, and the original Opana ER brand has been discontinued in the United States. Like all strong opioids, it carries significant risks, including constipation, drowsiness, respiratory depression, dependence, addiction, and overdose. It should only be used under the supervision of a qualified healthcare professional, exactly as prescribed, and extended-release tablets should always be swallowed whole. (Drugs.com)